The report specifies that the innovation takes advantage of the natural ability of nanoparticles to pass through the nasal cavity into the brain, a pathway already known to allow the entry of viruses and toxic substances.

This approach makes it possible to overcome the blood-brain barrier (BBB), which regulates the transport of substances between the blood and the central nervous system, enabling drugs to be delivered directly to the brain, thus reducing the need for high doses and side effects.

In the trials, an acetophenone aerosol was used to stimulate olfactory receptors and accelerate the delivery of manganese particles directly to tumor cells.

The results showed that the manganese particles are precisely localized in the tumor, without dispersing throughout the brain, offering new possibilities for the targeted treatment of glioblastoma, a disease with a 96 percent mortality rate.

This technology can be applied in the treatment of other brain diseases, such as Parkinson’s disease, dementia, and depression.

The technique, which has demonstrated efficacy in preliminary clinical trials, promises a significant advance in the development of more effective therapies for brain diseases.

jrr/abo/ro/gfa